IVVD vs MRNA

Invivyd (IVVD) retains a high-risk, high-reward profile, with its lead asset, VYD222 (pemivibart), having received regulatory authorization (e.g., EUA/BLA) in Q1 2025 for COVID-19 prevention in immunocompromised individuals. This critical milestone, anticipated in our previous analysis, validated the company's pivot. However, the subsequent commercialization efforts over the past year have been sl...

Moderna maintains a compelling, high-risk 10x growth potential within 3-5 years, primarily driven by its validated mRNA platform and an ambitious, diverse pipeline. The market cap has surged by 23% in 18 days to $19.65B, reflecting strong positive market sentiment and validation. This re-rating is likely due to robust early indicators for mRESVIA (RSV vaccine) market penetration and/or significant...